While having a potent effect on the malignant lymphoblastic cells, the normal CD5 + T cells remained mostly unaffected, demonstrating that CD5-IL15/IL15sushi CAR T cells could be a fast and safe method of treating patients with difficult-to-treat T cell lymphoblastic lymphoma/leukemia, even involving the CNS. This evidence concerns the gene CD5 and leukemia.